The CCL2-CCR2 axis activation within the TME is known to promote tumor angiogenesis and recruit TAMs and myeloid-derived suppressor cells (MDSCs) in various cancers, including sarcoma and breast cancer. This evidence concerns the gene CCL2 and neoplasm.